CNMD, US2074101013

CONMED stock falls 1.35 percent below an analyst target

Published on 09/25/2026 at 12:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CONMED stock carries a USD 41.40 consensus target from eight analysts on September 14, 2026. Q2 revenue reached USD 343.49 million versus USD 337.60 million expected.

CNMD, US2074101013, Illustration mit AI erstellt.

CONMED stock (ISIN US2074101013) fell 1.35 percent to USD 45.18 on the NYSE on September 24, 2026, leaving the medical-device company below its latest consensus target. The contrast is notable because second-quarter adjusted EPS and revenue both exceeded expectations.

Analyst target stays below price

According to MarketBeat on September 14, 2026, eight analysts assigned CONMED an average Reduce rating and a USD 41.40 12-month target. That target was 8.36 percent below the September 24 reference price of USD 45.18.

The analyst split comprised six Hold ratings and two Sell ratings. For investors, the numerical gap between operating delivery and valuation expectations is the central tension in the stock.

Second-quarter numbers beat consensus

Zacks reported on August 29, 2026, that CONMED posted adjusted EPS of USD 1.38 in Q2 2026, up 20 percent from the prior-year quarter. GAAP diluted EPS was USD 0.77, compared with USD 0.69 a year earlier.

Quarterly revenue reached USD 343.49 million, up 0.3 percent year over year and USD 5.89 million above the USD 337.60 million consensus estimate. The same release context put full-year 2026 adjusted EPS guidance at USD 4.48-4.60, above the previous USD 4.30-4.45 range.

Growth expectations move to the second half

At the Wells Fargo Healthcare Conference on September 9, 2026, management said Q2 organic constant-currency revenue growth was 6 percent and implied second-half growth of 6-8 percent, according to Investing.com. AirSeal, BioBrace and Buffalo Filter were identified as important contributors to that outlook.

CONMED develops surgical devices and equipment for specialties including orthopedics, general surgery, gynecology and thoracic surgery. Its second-half plan therefore depends on translating product-specific momentum into the 5-6 percent full-year revenue growth framework discussed at the conference.

Stock remains below yearly high

CONMED stood at USD 45.18 on the NYSE on September 24, 2026, after a USD 0.62 daily decline from the USD 45.80 prior close. The session range was USD 44.78-45.95, while the 52-week range was USD 31.44-53.66 and market capitalization was USD 1,353,197,385.